Replimune Group, Inc.
REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical triaā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.39
Price+1.70%
$0.19
1Y
Price
Market Cap
$957.057m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$313.940m
-27.0%
1y CAGR-21.8%
3y CAGR-28.3%
5y CAGREPS
-$3.38
-10.1%
1y CAGR-4.4%
3y CAGR-11.4%
5y CAGRBook Value
$166.160m
$332.388m
Assets$166.228m
Liabilities$111.586m
DebtDebt to Assets
33.6%
-0.3x
Debt to EBITDAFree Cash Flow
-$284.567m
-43.0%
1y CAGR-31.3%
3y CAGR-37.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company